AU2003278958A1 - (2s)-2amino-a-{(2-(ethanimidoylamino) ethyl)thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms - Google Patents

(2s)-2amino-a-{(2-(ethanimidoylamino) ethyl)thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms

Info

Publication number
AU2003278958A1
AU2003278958A1 AU2003278958A AU2003278958A AU2003278958A1 AU 2003278958 A1 AU2003278958 A1 AU 2003278958A1 AU 2003278958 A AU2003278958 A AU 2003278958A AU 2003278958 A AU2003278958 A AU 2003278958A AU 2003278958 A1 AU2003278958 A1 AU 2003278958A1
Authority
AU
Australia
Prior art keywords
ethanimidoylamino
2amino
thio
ethyl
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003278958A
Other languages
English (en)
Inventor
Stuart James Broughton
Rajinder Kumar Gharu
Mark Yuon Tuck Leow
Philip John Neale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SB Pharmco Puerto Rico Inc
Original Assignee
SB Pharmco Puerto Rico Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SB Pharmco Puerto Rico Inc filed Critical SB Pharmco Puerto Rico Inc
Publication of AU2003278958A1 publication Critical patent/AU2003278958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2003278958A 2002-06-19 2003-06-19 (2s)-2amino-a-{(2-(ethanimidoylamino) ethyl)thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms Abandoned AU2003278958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0214147.1A GB0214147D0 (en) 2002-06-19 2002-06-19 Formulations
GB0214147.1 2002-06-19
PCT/EP2003/006465 WO2004000296A1 (en) 2002-06-19 2003-06-19 (2s)-2amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
AU2003278958A1 true AU2003278958A1 (en) 2004-01-06

Family

ID=9938915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003278958A Abandoned AU2003278958A1 (en) 2002-06-19 2003-06-19 (2s)-2amino-a-{(2-(ethanimidoylamino) ethyl)thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms

Country Status (8)

Country Link
US (1) US20050222260A1 (enExample)
EP (1) EP1513511A1 (enExample)
JP (1) JP2005533075A (enExample)
AR (1) AR039691A1 (enExample)
AU (1) AU2003278958A1 (enExample)
GB (1) GB0214147D0 (enExample)
TW (1) TW200404766A (enExample)
WO (1) WO2004000296A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004017514D1 (de) * 2004-06-02 2008-12-11 Galephar M F Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
DE102011051304A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Wirkstoffmatrix
CN102908323B (zh) * 2012-10-30 2015-03-04 天津红日药业股份有限公司 一种含有莫西沙星的药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957087B1 (en) * 1994-06-15 2002-12-04 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
WO1996001128A2 (de) * 1994-07-04 1996-01-18 Schering Aktiengesellschaft Niedrig dosierte steroidtabletten, die gallussäureester als antioxidans enthalten, verfahren zur herstellung und die verwendung
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
GB0031179D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors

Also Published As

Publication number Publication date
AR039691A1 (es) 2005-03-09
EP1513511A1 (en) 2005-03-16
WO2004000296A1 (en) 2003-12-31
TW200404766A (en) 2004-04-01
US20050222260A1 (en) 2005-10-06
JP2005533075A (ja) 2005-11-04
GB0214147D0 (en) 2002-07-31

Similar Documents

Publication Publication Date Title
AU2003298010A1 (en) Non-hygroscopic formulation comprising a hydroscopic drug
AU2003222027A1 (en) Fast dissolving dosage forms having reduced friability
AU2002331743A1 (en) Handheld medication dosage calculator
GEP20094625B (en) Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
AU2003224743A1 (en) A low corrosive integrated process for preparing dialkyl carbonates
AU2003246734A1 (en) Medicament dispenser
AU2003287310A1 (en) Dispensing system for dispensing face masks from a stack
AU2003229738A1 (en) Medicament dispenser
AU2003254914A1 (en) Amino acid-containing chewable
AU2003201071A1 (en) Stable pharmaceutical compositions comprising ace inhibitor(s)
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
AU2003206718A1 (en) Dosage dispenser
AU2003278958A1 (en) (2s)-2amino-a-{(2-(ethanimidoylamino) ethyl)thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms
AU2003233083A1 (en) Medicament dispenser
AU2003257102A1 (en) Pharmaceutical dosage form comprising a sulfite compound
EP1389119A4 (en) PHARMACEUTICAL COMPOSITION BASED ON LYSOPHOSPHATIDE ACID
AUPS286302A0 (en) Medication inhaler
AU2003208621A1 (en) A pharmaceutical composition
IL164755A0 (en) Pharmaceutical composition containing a reversibleprotein pump inhibitor
AU2003227517A1 (en) Pharmacologically active salts
AU2003245774A1 (en) Pharmaceutical dosage form bearing pregnancy-friendly indicia
AU2003289782A1 (en) Valproic acid analogues and pharmaceutical compositions thereof
AU2003215607A1 (en) Compound containing creatine, an acid component and/or a complexing agent
AU2003216034A1 (en) Dermatological topical compositions and a process for the preparation thereof
AU2003270187A1 (en) A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase